Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1080/14760584.2021.1971522 http://scihub22266oqcxt.onion/10.1080/14760584.2021.1971522 34415818!8425437!34415818     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=34415818&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       Expert+Rev+Vaccines 2021 ; 20 (10): 1211-1220 Nephropedia Template TP {{tp|p=34415818|t=2021. To mix or not to mix? A rapid systematic review of heterologous prime-boost covid-19 vaccination |pdf=|usr=}}{{34415818}} gab.com Text To mix or not to mix A rapid systematic review of heterologous prime-boost covid-19 vaccination JO: Expert Rev Vaccines http://www.kidney.de/pget.php?&tw=1&pmid=34415818 #FOAvip INTRODUCTION: Coronavirus disease 2019 (COVID-19) has had an enormous impact worldwide, and vaccination is believed to be the method that will control the pandemic. Several types of vaccines developed using different platforms have been authorized, but the immunogenicity and reactogenicity of heterologous prime-boost vaccination with different vaccines remain largely unclear. AREAS COVERED: Electronic databases including PubMed, Embase, medRxiv, Research Square, and SSRN were searched to investigate the immunogenicity and reactogenicity associated with heterologous vaccination.As of 30 June 2021, four trials including 1,862 participants were identified. Heterologous administration of BNT162b2 (BNT) in ChAdOx1 (ChAd)-primed participants (ChAd/BNT) showed noninferior immunogenicity to homologous BNT administration (both prime and booster were BNT vaccines, BNT/BNT) with tolerable reactogenicity and higher T cell responses. Compared with homologous ChAdOX1 vaccination (ChAd/ChAd), heterologous ChAd/BNT was found to elicit higher immunogenicity (ChAd/BNT vs. ChAd/ChAd, antibody titer ratio: 9.2). EXPERT OPINION: Our systematic review found robust immunogenicity and tolerable reactogenicity of heterologous administration of a BNT162b2 boost in ChAdOx1-primed participants. An additional benefit of stronger T cellular immunity was also observed. Heterologous vaccination is a reasonable and feasible strategy to combat COVID-19. Further studies are warranted to confirm the benefits and identify the optimal combinations, doses, and intervals. Twit Text FOAVip To mix or not to mix A rapid systematic review of heterologous prime-boost covid-19 vaccination ????Expert Rev Vaccines http://www.kidney.de/pget.php?&tw=1&pmid=34415818 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34415818 #FOAvip English Wikipedia <ref>{{Cite pmid|34415818}}</ref> To mix or not to mix? A rapid systematic review of heterologous prime-boost covid-19 vaccination #MMPMID34415818 Chiu NC; Chi H; Tu YK; Huang YN; Tai YL; Weng SL; Chang L; Huang DT; Huang FY; Lin CY Expert Rev Vaccines 2021[Oct]; 20 (10): 1211-1220 PMID34415818show ga INTRODUCTION: Coronavirus disease 2019 (COVID-19) has had an enormous impact worldwide, and vaccination is believed to be the method that will control the pandemic. Several types of vaccines developed using different platforms have been authorized, but the immunogenicity and reactogenicity of heterologous prime-boost vaccination with different vaccines remain largely unclear. AREAS COVERED: Electronic databases including PubMed, Embase, medRxiv, Research Square, and SSRN were searched to investigate the immunogenicity and reactogenicity associated with heterologous vaccination.As of 30 June 2021, four trials including 1,862 participants were identified. Heterologous administration of BNT162b2 (BNT) in ChAdOx1 (ChAd)-primed participants (ChAd/BNT) showed noninferior immunogenicity to homologous BNT administration (both prime and booster were BNT vaccines, BNT/BNT) with tolerable reactogenicity and higher T cell responses. Compared with homologous ChAdOX1 vaccination (ChAd/ChAd), heterologous ChAd/BNT was found to elicit higher immunogenicity (ChAd/BNT vs. ChAd/ChAd, antibody titer ratio: 9.2). EXPERT OPINION: Our systematic review found robust immunogenicity and tolerable reactogenicity of heterologous administration of a BNT162b2 boost in ChAdOx1-primed participants. An additional benefit of stronger T cellular immunity was also observed. Heterologous vaccination is a reasonable and feasible strategy to combat COVID-19. Further studies are warranted to confirm the benefits and identify the optimal combinations, doses, and intervals. |BNT162 Vaccine[MESH] |COVID-19 Vaccines/*administration & dosage/immunology[MESH] |COVID-19/immunology/*prevention & control/virology[MESH] |Humans[MESH] |Immunogenicity, Vaccine[MESH] |SARS-CoV-2/immunology/isolation & purification[MESH]To mix or not to mix? A rapid systematic review of heterologous prime-(epmc).pdf DeepDyve Pubget Overpricing